La chaîne d'options affiche les données clés des options sur actions de Compass Pathways à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Compass Pathways..

Compass Pathways (NASDAQ:CMPS) Stock, Chaîne d'Options

COMPASS PATHWAYS PLC

Compass Pathways

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

COMPASS Pathways Plc - American Depository Shares

Compass Pathways PLC

Press Releases

Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

ATAI

CMPS

CYBN

MNMD

SAGE

Abeona Therapeutics

Annexon

Astria Therapeutics

Benitec Biopharma

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Crescent Biopharma

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Foghorn Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Heron Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Neurogene

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Comments

Compass Pathways

Compass Pathways (CMPS) Options

Compass Pathways (NASDAQ:CMPS) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL